Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: Results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 8, 2012, Pages 2714-2723

  Chindris, A M ^a   Diehl, N N ^a   Crook, J E ^a   Fatourechi, V ^b   Smallridge, R C ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; FOLLOW UP; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK ECHOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NECK; RADIOGRAPHY, THORACIC; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN ALFA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864823618     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3017     Document Type: Article

References (23)

1. Chen AY, Jemal A, Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807
2. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791
3. Morris LG, Myssiorek D 2010 Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 200:454-461
4. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885 (Pubitemid 30644169)
5. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441 (Pubitemid 36623351)
6. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057 (Pubitemid 41262253)
7. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
8. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, Fatourechi V 2007 Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92:82-87 (Pubitemid 46075007)
9. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussière F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, RicardM, Benhamou E 2007 Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 92:2487-2495 (Pubitemid 47037347)
10. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J 2010 Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 20:587-595
11. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G 2011 Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 96:1703-1709
12. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, Colato C, Zucchelli GC 2007 Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 67:434-441 (Pubitemid 47283844)
13. Rosario PW, Purisch S 2008 Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 68:338-342 (Pubitemid 351257849)
14. Giovanella L, Ceriani L, Ghelfo A, Keller F, Sacchi A, Maffioli M, Spriano G 2006 Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 44:648-652 (Pubitemid 43735641)
15. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352-1359
16. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A, Pacini F 2011 The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 34:e219-e223
17. Mazzaferri EL 2007 Will highly sensitive thyroglobulin assays change the management of thyroid cancer? Clin Endocrinol (Oxf) 67:321-323 (Pubitemid 47283837)
18. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 95:5241-5248
19. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625 (Pubitemid 32207469)
20. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L 2011 Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol (Oxf) 74:111-117
21. Nair A, Hansell DM 2011 European and North American lung cancer screening experience and implications for pulmonary nodule management. Eur Radiol 21:2445-2454
22. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh GL, Clemens MA 2003 Lung cancer screening with CT: Mayo Clinic experience. Radiology 226:756-761 (Pubitemid 36259152)
23. Choi JW, Lee JH, Baek JH, Choi BS, Jeong KS, Ryu JS, Kim TY, Kim WB, Shong YK 2010 Diagnostic accuracy of ultrasound and 18-FFDG PET or PET/CT for patients with suspected recurrent papillary thyroid carcinoma. Ultrasound Med Biol 36:1608-1615